In particular, MMP-9 attracted much attention, first when it was shown to cleave β-amyloid in vitro [221], followed by the clinical phenomenon that its plasma level is typically increased in Alzheimer’s disease patients [60,221]. Here, MMP9 is linked to early-onset autosomal dominant Alzheimer disease.